Isolation and characterization of a membrane protein from normal human erythrocytes that inhibits reactive lysis of the erythrocytes of paroxysmal nocturnal hemoglobinuria.
about
Structure of the CD59-encoding gene: further evidence of a relationship to murine lymphocyte antigen Ly-6 proteinExpression and function of membrane attack complex inhibitory proteins on thyroid follicular cellsBinding of human and rat CD59 to the terminal complement complexesTime course of complement activation and inhibitor expression after ischemic injury of rat myocardiumIsolation and characterization of a membrane protein from rat erythrocytes which inhibits lysis by the membrane attack complex of rat complementMolecular cloning of the rat analogue of human CD59: structural comparison with human CD59 and identification of a putative active siteInfectious diseases associated with complement deficiencies.Diagnostic surface expression of SWAP-70 on HIV-1 infected T cells.Leukemia arising out of paroxysmal nocturnal hemoglobinuria.Clonal evolution of aplastic anaemia to myelodysplasia/acute myeloid leukaemia and paroxysmal nocturnal haemoglobinuria.A recombination event in the 5' flanking region of the Ly-6C gene correlates with impaired expression in the NOD, NZB and ST strains of miceThe intrinsic complement regulator decay-accelerating factor modulates the biological response to vascular injuryHistorical aspects of paroxysmal nocturnal haemoglobinuria: 'defining the disease'.Hemoglobinuria misidentified as hematuria: review of discolored urine and paroxysmal nocturnal hemoglobinuria.Relationship between the membrane inhibitor of reactive lysis and the erythrocyte phenotypes of paroxysmal nocturnal hemoglobinuriaTargeting therapy to the neuromuscular junction: proof of concept.Cell surface complement regulators moderate experimental myasthenia gravis pathology.Compstatin: a C3-targeted complement inhibitor reaching its prime for bedside intervention.Complement in paroxysmal nocturnal hemoglobinuria: exploiting our current knowledge to improve the treatment landscape.A new aspect of the molecular pathogenesis of paroxysmal nocturnal hemoglobinuria.Antibody-dependent complement-mediated cytotoxicity in sera from patients with HIV-1 infection is controlled by CD55 and CD59Tubulointerstitial injury induced in rats by a monoclonal antibody that inhibits function of a membrane inhibitor of complement.Lysis of complement-sensitive Entamoeba histolytica by activated terminal complement components. Initiation of complement activation by an extracellular neutral cysteine proteinaseNecrotizing Fasciitis in Paroxysmal Nocturnal Hemoglobinuria.Development of complement therapeutics for inhibition of immune-mediated red cell destructionSequence-specific 1H-NMR assignments and folding topology of human CD59.New Insights on Complement Inhibitor CD59 in Mouse Laser-Induced Choroidal Neovascularization: Mislocalization After Injury and Targeted Delivery for Protein Replacement.Role of virion-associated glycosylphosphatidylinositol-linked proteins CD55 and CD59 in complement resistance of cell line-derived and primary isolates of HIV-1Paroxysmal nocturnal hemoglobinuria: a complement-mediated hemolytic anemiaSelectivity of C3-opsonin targeted complement inhibitors: A distinct advantage in the protection of erythrocytes from paroxysmal nocturnal hemoglobinuria patients.Paroxysmal nocturnal hemoglobinuria and glycosyl phosphatidylinositol anchored proteins that regulate complement.Structural composition and functional characterization of soluble CD59: heterogeneity of the oligosaccharide and glycophosphoinositol (GPI) anchor revealed by laser-desorption mass spectrometric analysis.Extraocular muscle susceptibility to myasthenia gravis: unique immunological environment?Rational engineering of a minimized immune inhibitor with unique triple-targeting properties.Assembly and deacetylation of N-acetylglucosaminyl-plasmanylinositol in normal and affected paroxysmal nocturnal hemoglobinuria cells.Anti-Complement Treatment in Paroxysmal Nocturnal Hemoglobinuria: Where we Stand and Where we are Going.Laboratory tests for paroxysmal nocturnal hemoglobinuria.Paroxysmal nocturnal hemoglobinuria and the age of therapeutic complement inhibition.Hematopoietic stem cell transplantation for aplastic anemia and paroxysmal nocturnal hemoglobinuria: current evidence and recommendations.Markedly enhanced susceptibility to experimental autoimmune myasthenia gravis in the absence of decay-accelerating factor protection.
P2860
Q24293224-49610783-0575-4B0A-A570-EB7F83BE64B4Q24541460-045B4FE8-4CA9-485D-B786-BFAC310AE98DQ28565870-D2E13BCA-4427-4AF4-8849-E20C6A56D306Q28568260-87915232-4274-45B2-AB0D-C7F9745FE2A8Q28569128-BF092C36-EE09-494B-8088-BFAACA24CEC9Q28572539-95B5A00A-9BE8-486A-A312-36F947EEA3C9Q30450183-F34F5F6D-D9DD-4210-AC24-A4B1858DBD55Q33237009-5005531C-7C76-4932-861E-AD9E34C75A97Q33536877-54F9BD96-7A56-4F35-A4AC-9B349060A12EQ33604344-9CEAD4C7-35C1-46FD-B29C-A9C0AF7FB692Q33924154-51ED2B2E-3B14-438C-8C9F-7CC062FC04D9Q33990334-A8FC3A3D-8CA8-47A1-AC0A-97C42290C028Q34120817-AB4A5010-3C3F-41D4-A60A-EB0756C2C26CQ34462881-6FE05B7F-0B51-4B6C-812E-C57FE32E3F66Q34578218-CCBC3375-985F-43D0-9A59-A59204B97618Q34974981-C5338499-87DF-4834-8C9A-825A386921A9Q35021497-88273986-EE02-45E6-8F6A-3D0DFE5FD9AFQ35236103-C57B07EE-D267-4937-93D6-534700597F71Q35252156-840C42EC-270D-499C-8B09-25F90E0D6E50Q35670980-BCB7F498-4DCE-40B9-89D2-1A43A2A7B22CQ35763321-66E2B876-0384-4186-A1A5-C31BD4531170Q35766363-13D156D5-0EA7-446E-8CDF-72601E28CE65Q35816948-9FCBCE3A-9254-43CA-A73E-C9F5A7423F80Q35992349-FEF9C5A3-1992-46B4-A2BB-4CF72014A0FCQ36222203-AD4CB2BD-447F-4FE9-946B-D824C84316D9Q36277854-86F46605-8B15-42A1-97FF-BBF8999CA1BDQ36319522-F991DBC2-1520-46F3-A630-A33FD90D4ED1Q36365174-6C90D234-AEA8-47C0-B4E3-601D2068BFC3Q36416292-1669563F-6377-43A2-8626-19245A392342Q36563619-4A270CFA-F663-4631-A802-958D93A47AC9Q36691261-4977917A-BD9B-467B-9EE8-E30D1E340D81Q36803615-E74180F8-1F94-4844-988C-A4C24B6AA078Q36858180-1F4DB1B1-A70D-4197-89F5-91ABF5B37C69Q37300691-87DE055B-4999-4325-A308-83E1404A6117Q37496518-05ABA329-049C-47E2-A4EE-742904485C1BQ37724607-150DA6FB-3CAF-4DA4-87BA-783F92D19F33Q38152731-76F7C040-F407-43B8-ACF4-3E2331F35250Q38156229-440517AF-BE31-4524-A7E4-6AEFBF079491Q38261555-6DB1EAFA-0D8A-4584-BEDD-A68F1052FCD3Q39740020-508557DD-5343-4DC1-ACA0-2C0097E7E3DD
P2860
Isolation and characterization of a membrane protein from normal human erythrocytes that inhibits reactive lysis of the erythrocytes of paroxysmal nocturnal hemoglobinuria.
description
1989 nî lūn-bûn
@nan
1989 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
1989 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
1989年の論文
@ja
1989年論文
@yue
1989年論文
@zh-hant
1989年論文
@zh-hk
1989年論文
@zh-mo
1989年論文
@zh-tw
1989年论文
@wuu
name
Isolation and characterization ...... smal nocturnal hemoglobinuria.
@ast
Isolation and characterization ...... smal nocturnal hemoglobinuria.
@en
Isolation and characterization ...... smal nocturnal hemoglobinuria.
@nl
type
label
Isolation and characterization ...... smal nocturnal hemoglobinuria.
@ast
Isolation and characterization ...... smal nocturnal hemoglobinuria.
@en
Isolation and characterization ...... smal nocturnal hemoglobinuria.
@nl
prefLabel
Isolation and characterization ...... smal nocturnal hemoglobinuria.
@ast
Isolation and characterization ...... smal nocturnal hemoglobinuria.
@en
Isolation and characterization ...... smal nocturnal hemoglobinuria.
@nl
P2093
P2860
P356
P1476
Isolation and characterization ...... smal nocturnal hemoglobinuria.
@en
P2093
C J Parker
L A Wilcox
L R Fredrick
M H Holguin
N J Bernshaw
P2860
P356
10.1172/JCI114172
P407
P577
1989-07-01T00:00:00Z